The interaction of Fas (CD95), a member of the tumor necrosis factor receptor (TNFR) family, and its ligand (FasL) triggers programmed cell death (apoptosis) and is involved in the regulation of immune responses. Although the Fas–FasL interaction is conserved across species barriers, little is currently known about the molecular details of this interaction. Our aim was to identify residues in Fas that are important for ligand binding. With the aid of a Fas molecular model, candidate amino acid residues were selected in the Fas extracellular domain 2 (D2) and D3 and subjected to serine-scanning mutagenesis to produce mutant Fas molecules in the form of Ig fusion proteins. The effects of these mutations on FasL binding was examined by measuring the ability of these proteins to inhibit FasL-mediated apoptosis of Jurkat cells and bind FasL in ELISA and BIAcore™ assays. Mutation of two amino acids, R86 and R87 (D2), to serine totally abolished the ability of Fas to interact with its ligand, whereas mutants K84S, L90S, E93S (D2), or H126S (D3) showed reduced binding compared with wild-type Fas. Two mutants (K78S and H95S) bound FasL comparably to wild type. Therefore, the binding of FasL involves residues in two domains that correspond to positions critical for ligand binding in other family members (TNFR and CD40) but are conserved between murine and human Fas.
Skip Nav Destination
Article navigation
21 April 1997
Brief Definitive Report|
April 21 1997
Identification of Amino Acid Residues Important for Ligand Binding to Fas
Gary C. Starling,
Gary C. Starling
From Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121
Search for other works by this author on:
Jürgen Bajorath,
Jürgen Bajorath
From Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121
Search for other works by this author on:
John Emswiler,
John Emswiler
From Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121
Search for other works by this author on:
Jeffrey A. Ledbetter,
Jeffrey A. Ledbetter
From Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121
Search for other works by this author on:
Alejandro Aruffo,
Alejandro Aruffo
From Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121
Search for other works by this author on:
Peter A. Kiener
Peter A. Kiener
From Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121
Search for other works by this author on:
Gary C. Starling
From Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121
Jürgen Bajorath
From Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121
John Emswiler
From Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121
Jeffrey A. Ledbetter
From Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121
Alejandro Aruffo
From Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121
Peter A. Kiener
From Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121
Address correspondence to Gary C. Starling, Bristol-Myers Squibb Pharmaceutical Research Institute, 3005 First Avenue, Seattle, WA 98121.
Received:
January 29 1997
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1997
J Exp Med (1997) 185 (8): 1487–1492.
Article history
Received:
January 29 1997
Citation
Gary C. Starling, Jürgen Bajorath, John Emswiler, Jeffrey A. Ledbetter, Alejandro Aruffo, Peter A. Kiener; Identification of Amino Acid Residues Important for Ligand Binding to Fas. J Exp Med 21 April 1997; 185 (8): 1487–1492. doi: https://doi.org/10.1084/jem.185.8.1487
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement